Eckert and Ziegler

Valuation Analysis

About the Company

Eckert and Ziegler en bref

Eckert and Ziegler (EUZ.DE) is currently trading at 13,61 € with a market capitalization of 740 M €. The trailing P/E ratio stands at 17.23x, with a forward P/E of 15.48x. The 52-week range spans from 13,09 € to 21,70 €; the current price is 37.3% below the yearly high. Year-over-year revenue growth stands at +7.0%. The net profit margin stands at 15.61%.

💰 Dividende

Eckert and Ziegler pays an annual dividend of 0,22 € per share, representing a yield of 1.62%. The payout ratio stands at 21.1%.

📊 Avis des analystes

3 analystes évaluent Eckert and Ziegler (EUZ.DE) au consensus : Achat Fort. L'objectif de cours moyen est de 21,60 €, soit un potentiel de +58.71% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 20,30 € à 23,00 €.

Eckert and Ziegler : la thèse d'investissement en détail

Eckert and Ziegler (EUZ.DE) operates in the Healthcare — specifically Medical Devices — and is headquartered in Germany. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

The combination of a 48.91% gross margin and 21.89% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Free cash flow is positive and net margins stand at 15.61%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Wall Street consensus sits at Strong Buy with an average price target implying roughly 58.71% upside from current levels — analyst sentiment is firmly constructive.

Valorisation en contexte

With a PEG ratio of 0.91, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 8.53x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 15.48x is meaningfully below the trailing 17.23x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 58.71% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to market-like volatility.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Eckert and Ziegler?

Compare top-rated brokers — low fees, trusted providers, fully regulated.